Healthpeak & Brookfield Form Outpatient Medical Joint Venture
DOC's $2.1 billion outpatient medical portfolio joint venture with BAM provides long-term capital while preserving control and future growth potential.
DOC - Healthpeak Properties, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$22.14
DETAILS
HIGH:
$24.00
LOW:
$19.00
MEDIAN:
$22.00
CONSENSUS:
$22.14
DOWNSIDE:
0.23%
Stock News
Healthpeak Properties and Brookfield Form a $2.1 Billion Strategic Joint Venture
DENVER & NEW YORK--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak") and Brookfield Asset Management (NYSE: BAM, TSX: BAM) (“Brookfield”), today announced the formation of a long-term strategic capital partnership through a joint venture involving a portfolio of outpatient medical buildings across the United States.The portfolio contributed by Healthpeak is comprised of 86 properties totaling approximately 5.6 million square feet, valued at approximately $2.1 billion. The p.
3 Healthcare REITs to Buy as America Ages in July
America's demographic clock keeps ticking, and the money is following the wrinkles.
Top 10 Dividend Stocks to Buy in 2026
In this bonus episode of The Morning Filter podcast, co-hosts Dave Sekera and Susan Dziubinski talk dividend stock investing. They unpack the performance of dividend stocks during the first half of 2026, including how the performance of dividend stocks stacked up against that of the broad market and which sectors drove the performance.
Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Third Quarter of 2026
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced that on July 9, 2026, its Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for the third quarter of 2026, payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date in the table below. The.
3 REITs to Buy for Passive Income in July
Income investors entering July 2026 are getting a friendlier setup than they had six months ago.
Healthpeak Properties Gains 28% in 3 Months: Will the Trend Last?
DOC surges 28% in three months as leasing, occupancy gains and Janus Living growth support its shift toward labs and outpatient assets.
5 High-Yielding S&P 500 Stocks Trading at Double-Digit Discounts Are Incredible Strong Buys Now
The Standard and Poor's 500 is a stock market index that tracks the performance of the 500 biggest companies in the United States. It is considered a top indicator of the U.S. stock market's health. It is a market-capitalization-weighted index of the 500 leading publicly traded companies in the U.S. Typically, larger companies significantly impact... 5 High-Yielding S&P 500 Stocks Trading at Double-Digit Discounts Are Incredible Strong Buys Now
Healthpeak Properties: This 6% Yielding REIT Has More Room To Run
Healthpeak Properties remains a Strong Buy, combining value, income, and recovery potential in healthcare real estate. DOC's outpatient medical and life sciences segments show improving occupancy, strong lease spreads, and embedded rent escalators supporting steady growth. The Janus Living spin-off unlocks value in senior housing, with DOC retaining 82% ownership and benefiting from high segment growth.
Healthpeak Properties Publishes Its 15th Annual Corporate Impact Report
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. ("Healthpeak") (NYSE: DOC) announced today the release of its 15th annual 2025 Corporate Impact Report (the "Report"). The Report highlights Healthpeak's continued focus on building a resilient portfolio, advancing sustainability goals, fostering a workplace culture guided by its WE CARE core values, and promoting sound corporate governance and transparency. "As one of the nation's leading owners of Outpatient Medical, Lab, and Senior Housing.
Healthpeak Properties Announces Dates of Second Quarter 2026 Earnings Release, Conference Call, and Webcast
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report second quarter 2026 financial results after the close of trading on the New York Stock Exchange on Tuesday, August 4, 2026. Healthpeak will host a conference call and webcast on Wednesday, August 5, 2026 at 10:00 a.m. Eastern Time to review its financial performance and operating results. The conference call can b.
Alexandria Or Healthpeak? Your Risk Tolerance May Determine The Winner
Healthpeak Properties offers a diversified, growth-oriented REIT portfolio with 40% life science exposure and robust 2026 FFO guidance of $1.71–$1.75 per share. DOC maintains conservative 37.3% leverage, investment-grade ratings with a stable outlook, and a well-covered 6.2% monthly dividend supported by a 70% payout ratio. Alexandria Real Estate is in portfolio contraction mode, facing sector oversupply and negative re-leasing spreads, with 2026 FFO guidance annualized at $5.80 per share.
Healthpeak (DOC) Down 2.2% Since Last Earnings Report: Can It Rebound?
Healthpeak (DOC) reported earnings 30 days ago. What's next for the stock?
EU clears Arla's DMK, DOC buyout, citing no competition concerns
The European Union on Thursday approved Arla Foods' acquisition of Germany's DMK and Dutch cooperative DOC without conditions, saying the deal would not harm competition in the European Economic Area.
Healthpeak Properties Gains 22.7% Year to Date: Will the Trend Last?
DOC gains 22.7% year-to-date, driven by leasing momentum, rising occupancy and Janus Living growth.
This Healthcare REIT Stands Out With 6.3% Yield
With a 6.3% yield, REIT stock HealthPeak Properties is among the highest-paying players in the S&P 500, well above the current 1% average.
Healthpeak Properties: A Healthy Balance Sheet And Growth Opportunities Outweigh Risk Concerns
Healthpeak Properties earns a buy rating, driven by strong capital allocation and a compelling portfolio mix across Outpatient Medical, Labs, and Senior Housing. DOC trades at ~11x P/FFO with a >6% dividend yield, offering both stability and upside from secular and cyclical trends in its segments. Recent moves—like the Janus Living IPO, opportunistic acquisitions, and disciplined share buybacks—unlock value and enhance capital efficiency.
Healthpeak Properties: Lab Weakness Creates A Major Re-Rating Opportunity
Healthpeak Properties is still a Buy after the recent rally, supported by strong earnings, a robust dividend, and significant re-rating potential. DOC's Q1 2026 beat on FFO and revenue; completed the Janus Living IPO; and executed major acquisitions, reinforcing portfolio value and future growth prospects. With $1.17 billion in cash and a sustainable 6.2% monthly dividend yield (~70.7% payout ratio), DOC's dividend looks safe despite macroeconomic headwinds, leaving room for more buybacks.
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a... Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More
The Overlooked Trend That Could Supercharge REIT Dividends
REITs are undervalued and out-of-favor compared to AI-driven tech stocks, creating a contrarian opportunity. Rising construction costs are constraining new supply, increasing the value and pricing power of existing REIT portfolios. Multiple REITs, including AH REALTY TRUST, Chiron Real Estate, Piedmont Realty Trust, and Healthpeak Properties, report higher replacement costs and favorable re-leasing spreads.
Price Targets
Healthpeak Properties price target raised to $22 from $20 at Wells Fargo
$22.00
(was $21.66)
Wells Fargo
Healthpeak Properties initiated with an Equal Weight at Barclays
$23.00
(was $21.75)
Barclays
Healthpeak Properties price target raised to $24 from $21 at Mizuho
$24.00
(was $21.86)
Vikram Malhotra
·
Mizuho Securities
Healthpeak Properties price target raised to $24 from $20 at BMO Capital
$24.00
(was $20.69)
BMO Capital
Healthpeak Properties downgraded to Equal Weight at Morgan Stanley
$22.00
(was $20.77)
Ronald Kamdem
·
Morgan Stanley
Healthpeak Properties price target raised to $21 from $19 at Scotiabank
$21.00
(was $20.07)
Scotiabank
Healthpeak Properties price target raised to $20 from $18 at Morgan Stanley
$20.00
(was $19.70)
Ronald Kamdem
·
Morgan Stanley
Healthpeak Properties price target raised to $19 from $17 at UBS
$19.00
(was $19.78)
UBS
Healthpeak Properties price target lowered to $18 from $21 at Morgan Stanley
$18.00
(was $15.83)
Morgan Stanley
Healthpeak Properties initiated with a Neutral at UBS
$17.00
(was $17.37)
UBS
Healthpeak Properties price target lowered to $18 from $19 at Wells Fargo
$18.00
(was $16.92)
John Kilichowski
·
Wells Fargo
Healthpeak Properties initiated with a Neutral at Goldman Sachs
$17.00
(was $17.04)
Goldman Sachs
Healthpeak Properties price target lowered to $17 from $20 at Cantor Fitzgerald
$17.00
(was $16.16)
Cantor Fitzgerald
Healthpeak Properties downgraded to Hold from Buy at Jefferies
$17.00
(was $16.66)
Jefferies
Healthpeak Properties price target lowered to $21 from $22 at Evercore ISI
$21.00
(was $16.80)
Evercore ISI
Healthpeak Properties initiated with a Neutral at Cantor Fitzgerald
$20.00
(was $19.15)
Cantor Fitzgerald
Healthpeak Properties price target lowered to $22 from $23 at Evercore ISI
$22.00
(was $18.08)
Evercore ISI
Healthpeak upgraded to Outperform from Market Perform at Raymond James
$20.00
(was $18.25)
Jonathan Hughes
·
Raymond James
Healthpeak Properties price target lowered to $21 from $22 at Morgan Stanley
$21.00
(was $17.75)
Morgan Stanley
Healthpeak Properties price target lowered to $21 from $22 at Baird
$21.00
(was $17.22)
Robert W. Baird